Page 1052

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

Evaluation of Antibiotic Therapy from Discovery to Modern

Challenges

Santosh Kumar; Dr. Sunita Kumari

; Associate Professor, Dr. Jyoti Gupta;

Professor, Shalini Devi

Associate Professor, IEC School of Pharmacy, IEC University Baddi, Himachal Pradesh – 174103

Corresponding Author

DOI: https://doi.org/10.51583/IJLTEMAS.2026.15020000092

Received: 25 February 2026; Accepted: 02 March 2026; Published: 19 March 2026

ABSTRACT

Bacterial infections obtained in hospitals result in longer hospital stays and higher mortality rates.

Antibioticresistant bacteria worsen the issue by impeding or delaying effective therapy. Treatment regimens that

use multiple antibiotics may be employed to manage antibiotic resistance and guarantee effective therapy. This

includes giving patients medicine mixtures (combination therapy), randomly allocating pharmaceuticals to

various patients (mixing), and routinely changing the hospital's default medication from drug A to drug B and

back (cycling). The potential of antibiotic combination therapy, mixing, and cycling has been evaluated for over

two decades using mathematical models. However, despite trends in their rankings among research, the picture

is still shockingly ambiguous and inconsistent, with no clear consensus on which strategy most effectively limits

the emergence and spread of antibiotic resistance. In this paper, we examine previous modeling research and

illustrate through examples how methodological considerations make it more difficult to produce a coherent

image. These elements include the model's implementation and analysis, as well as the selection of the criterion

used to compare the protocols' impacts. After that, we talk about how to advance and offer ideas for future

modeling paths, emphasizing the need for standardized evaluation metrics, realistic clinical assumptions,

integration of empirical data, and interdisciplinary collaboration to better inform evidence-based antibiotic

stewardship policies.

Keywords: Antibiotic, Antibiotic Resistance, Antimicrobial Resistance (AMR)

INTRODUCTION

Prior to the invention of antibiotics, the main causes of death were infectious diseases like sepsis, pneumonia,

and tuberculosis. Penicillin's clinical use in the 1940s marked the beginning of the antibiotic era and transformed

medical care.[1] Many antibiotic classes were developed or found in the ensuing decades, greatly extending life

expectancy and enhancing medical results. However, antibiotic resistance is now a serious problem that calls for

innovation in global policy, drug development, and management.[2]

Historical Development of Antibioticsthe Pre-Antibiotic Era

Treatments for infections were mostly empirical and ineffectual before the 20th century. Bacterial illnesses

caused a significant death rate, particularly during pandemics and conflicts.[3]

The Discovery of Penicillin

Alexander Fleming noticed in 1928 that a mold called Penicillium notatum prevented germs from growing.

During World War II, penicillin became the first commonly used antibiotic as a result of this discovery. Later,

scientists like Ernst Boris Chain and Howard Florey advanced large-scale production.[4]

Page 1053

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

Figure 1. Chemical Structure of the Penicillin Core (6-Aminopenicillanic Acid) Showing the β-Lactam

Ring and Thiazolidine Ring.

The Golden Age of Antibiotics (1940S–1960S)

During this time, important groups of antibiotics were discovered, including: Streptomycin and other

aminoglycosides are examples. Tetracyclines Macrolides Cephalosporins These findings greatly decreased the

death rate from illnesses like bacterial endocarditis and tuberculosis. [5]

The Slowdown in Discovery

Due to scientific, financial, and regulatory obstacles, the development of antibiotics stagnated after the 1970s.

Investments in pharmaceuticals have switched to more lucrative therapies for chronic illnesses.[6]

Mechanisms of Action

Antibiotics target vital bacterial functions, such as Inhibitors of Cell Wall Synthesis o Beta-lactams (like

cephalosporins and penicillins) o Glycopeptides (like vancomycin), Inhibitors of Protein Synthesis Tetracyclines,

Aminoglycosides, and Macrolides. Rifamycins, fluoroquinolones, and inhibitors of nucleic acid synthesis.

Inhibitors of Metabolic Pathways o Sulfonamides. These substances can kill or suppress bacteria without

endangering human cells thanks to their selective toxicity. [7]

Clinical Impact of Antibiotic Therapy

Antibiotics have made it possible for:

Safe surgical techniques, Transplanting organs Chemotherapy for cancer, Critical care for newborns. The

mid20th century saw a sharp decline in bacterial infection-related mortality. Effective antimicrobial therapy

contributed to an increase in life expectancy worldwide.[8]

Emergence of Antimicrobial Resistance (Amr)

Resistance Mechanisms Resistance in bacteria is developed by: Drug inactivation by enzymes, such as

betalactamases, Modified medication targets Efflux pumps, Decreased permeability of the membrane Resistance

propagation is accelerated by horizontal gene transfer and genetic changes. [9]

Multidrug-Resistant Organisms

Among the examples are:

Resistance to methicillin MRSA, or Staphylococcus aureus • Enterobacteriaceae resistant to carbapenem (CRE),

Mycobacterium tuberculosis that is resistant to drugs Longer hospital stays, more medical expenses, and higher

mortality are all caused by AMR. [10]

Page 1054

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

Factors Contributing to Resistance

Overprescription and inappropriate use, Patient non-adherence, Antibiotic use in agriculture, Ineffective

infection control procedures,International trade and travel, The World Health Organization has declared AMR

one of the top global public health threats.[11]

Modern Strategies and Innovations

Stewardship of Antimicrobials. In order to lower resistance and enhance patient outcomes, programs are designed

to maximize the use of antibiotics.[12]

Development Of Novel Agents

Research is concentrated on: Novel classes of antibiotics, Combination treatments Additionally, beta-lactamase

inhibitors, Anti-virulence treatments [13]

Alternative Approaches

The use of bacteriophages, Immunotherapy,Antimicrobial tactics based on C RISPR,Modification of the

microbiome[14]

Global Initiatives

To tackle AMR, organizations like the World Health Organization support awareness campaigns, policy

coordination, and surveillance.[15]

Challenges In The 21st Century

The pipeline for antibiotics is dwindling. Financial obstacles to the development of new drugs The spread of

germs resistant to pandemics, in low-income areas, access to effective antibiotics is restricted. A major ethical

and policy dilemma is still striking a balance between stewardship and access.[16]

Future Directions

Offering rewards for pharmaceutical research Rapid technology for diagnosis, Tailored antimicrobial treatment,

More robust worldwide surveillance networks, To maintain the effectiveness of antibiotics, international

cooperation is crucial. [17]

Mechanism Of Antibiotic Resistance

The Antimicrobial Resistance Genetic Basis

Bacteria have remarkable genetic adaptability, which allows them to survive a wide range of environmental

threats, including the presence of antibiotic chemicals.[18] Because of their innate resistance, bacteria that share

a biological niche with organisms that manufacture antibiotics have long-standing defenses against the harmful

effects of the antibiotic molecule, which allows them to thrive in its presence.[19] Bacteria use two primary

genetic strategies to adapt to the antibiotic "attack" from an evolutionary perspective:i) mutations in the gene or

genes commonly associated with the mechanism of action of the compound, and ii) horizontal gene transfer

(HGT) to obtain foreign DNA coding for resistance determinants.[20]

Antibiotic Resistance Occurs by Following Mechanisms

Production of enzymes, Target site modification, Efflux pumps, Less permeability, Formation of bio films,

Transfer of genes horizontally, Overproduction of native PBPs, mutations in those PBPs, and the creation of new

PBPs resistant to? The main reasons why Gram-positive bacteria develop resistance to -lactam inhibition are?-

lactam medications.[21] The proliferation of Staphylococcus aureus strains resistant to cephalosporins and

Page 1055

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

methicillin and other semi-synthetic penicillins is a concern these days. The figure illustrates the resistance

mechanism: When an antibiotic is not present, both domains of a high-molecular-weight PBP take part in

peptidoglycan biosynthesis (A); when an antibiotic is present, only the glycosyltransferase domain of a

highmolecular-weight PBP is active, while the transpeptidase domain is acylated and does not form crosslinks.

The resistant strain's acquired low-molecular-weight PBP2a (B) demonstrates transpeptidase activity.[22] After

that, cell viability is recovered. The gene mec A encodes the PBP2a enzymes.[23]

Efflux Pump

A range of antibacterial classes, including fluoroquinolones and protein synthesis inhibitors?-lactams,

carbapenems, and polymyxins is affected by the resistance mechanism of the efflux pump.The five primary

families of efflux pumps are the ATP-binding cassette family (ABC), the resistance-nodulation-cell-division

family (RND), the multidrug and toxic compound extrusion family (MATE), the major facilitator superfamily

(MFS), and the small multidrug resistance family (SMR).[24] These families differ in their structural

conformation, energy source, range of substrates they can extrude, and types of bacterial species they

inhabit.[25]The efflux pumps found in bacterial cytoplasmic membranes aggressively move toxic substances out

of the cell. This mechanism is known as drug efflux. [26]The slow process of antibiotic efflux gives bacteria

time to adapt and become resistant to antibiotics. This could be due to either mutations or modifications to the

antibiotic target. [27]The energy source that each of the five major kinds of efflux pumps uses sets them apart:

The principal organizer (MF). RND (resistance nodulation-division) and MATE (multidrug and toxic efflux)

Small multidrug resistance (SMR) (ABC) ATP binding cassette.[28]

Figure 2. Schematic Representation of TolC-Dependent Multidrug Efflux Pump Systems in GramNegative

Bacteria.

Decreased Permeability

Gram-negative bacteria protect themselves from antibiotics by decreasing their permeability. By altering the

bacteria's outer membrane, this mechanism reduces the amount of antibiotics that may enter the cell.[29]Reduced

permeability can lead to the development of crossresistance in a number of antibiotic families. It might also

increase the effectiveness of other resistance mechanisms in generating resistance.[30] Many of the antibiotics

used in modern medicine target intracellular bacteria in the cytoplasmic membrane, also referred to as the inner

membrane.[31] Therefore, the chemical must penetrate the cytoplasmic and/or outer membrane in order to have

Page 1056

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

an antibacterial effect. Bacteria have developed defense mechanisms that decrease the absorption of the

antimicrobial chemical, preventing it from reaching its intracellular or periplasmic target.[32]For the reasons

outlined above, this mechanism, which limits the influx of chemicals from the external environment, is

particularly important in gramnegative bacteria. The first line of protection against the introduction of many

dangerous substances, including antibacterial agents, is really the outer membrane.[33] Changes in the

permeability of the outer membrane have the greatest effect on hydrophilic drugs, such as?-lactams, tetracyclines,

and some fluoroquinolones, since they often use water-filled diffusion channels termed porins to penetrate this

barrier.[34]

Biofilm Formation

Concerns in a variety of domains, such as public health, medicine, and the pharmaceutical industry, have drawn

a lot of attention to the formation of biofilms.[35] The amazing ability of bacteria that form biofilms to develop

treatment resistance increases morbidity and death. As a result, the healthcare sector is experiencing extreme

financial duress.[36] The complex process of biofilm development is impacted by several factors. Many efforts

have been made to understand the mechanisms behind the production of biofilms; these efforts have provided

important insights into the mechanisms that the treatment should focus on.[37] Because the biofilm state makes

the bacterial pathogens significantly resistant to drugs, targeting diseases within biofilm is a lucrative effort.The

burden of antimicrobial therapy can be reduced by repurposing the available drugs to eradicate the pathogen.[38]

Additionally, biofilm former-induced infections have been found in humans, animals, and plants.[39] The

development of novel strategies, including bioinformatics tools, for treating and preventing the production of

biofilms has received a lot of attention.[40] Bacterial biofilms are a significant cause of persistent infections

because of their heightened resistance to antibiotics and disinfectants, which can disrupt phagocytosis and other

immune system processes.[41] Because the microorganisms in biofilms are less susceptible to different

antimicrobial medications, biofilms provide an impending therapeutic conundrum.[42] Biofilm resistance may

lead to antibiotic tolerance or resistance.Microorganisms can build defenses against antimicrobials by acquiring

foreign genetic material coding for resistance determinants through genetic mutation or horizontal gene transfer

(HGT) in biofilm EPS.[43] AMR is produced by a variety of mechanisms, including as reduced permeability or

restricted access to antimicrobials, mutational changes in antibiotic targets, and enzymatic destruction of the

antimicrobials by hydrolysis or chemical change.[44] Antibiotic resistance (ABR) is a subset of antimicrobial

resistance (AMR) because antibiotics kill germs, but the bacteria become resistant to them.

Figure 3. Stages of Biofilm Formation and Development in Bacteria HORIZONTAL GENE TRANSFER

Horizontal gene transfer is a major factor in the spread of antibiotic resistance. Numerous routes can occur

between bacteria of the same or different species as a result of HGT.[45] The following are some ways that HGT

contributes to antibiotic resistance:

Page 1057

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

Resistance Gene Transfer

A bacterium can disseminate its resistance to antibiotics to other bacteria by horizontal gene transfer, or HGT.

Plasmids Plasmids are small, circular DNA fragments that bacteria commonly use to convey genes.[46] The

conjugation process involves the physical transfer of genes, such as plasmids, between bacteria. Biofilms are a

hotspot for HGT and have been connected to serious infections and diseases.[47] Antibiotic resistance is

influenced by several factors, such as:

Figure 4. Mechanisms of Horizontal Gene Transfer Responsible for the Spread of Antibiotic Resistance in

Bacteria

Human behavior: overprescribing, overusing, and failing to take antibiotics as directed. Hygiene: A combination

of inadequate hygiene and a failure to prevent and control infections.[48] Travel: People who travel throughout

the world have the potential to discharge antibiotics and resistant bacteria into waste systems, water bodies, and

soil. 3. Environmental factors.[49] Animal-related practices: antibiotics are widely used in cattle and aquaculture.

Wildlife: Spread through encroachment on their habitat and interactions with wildlife.[50]

Soil characteristics include loam, depth, temperature, and nutritional value.

Socio demographic traits include living in an urban area, having a low salary, and being a migrant. The patient's

clinical information, including the disease's current state and particular laboratory results.[51] The length of stay

in a hospital after being admitted

Impact of Antibiotic Resistance

When assessing the impact of antibiotic resistance, the patient, the hospital, a third-party payer, and society can

all be involved.[52]

Hospital Perspective

The hospital perspective has been the primary focus of research on the impacts of resistance.[53] Data about in-

hospital morbidity, mortality, and the costs associated with antibiotic resistance are very easy to obtain, and

hospitals are most likely to respond to information assessed at the hospital level.[54]

Patient Perspective

Mortality and hospitalization length measures quantify the short-term direct impact of resistance on the affected

patient.[55] However, resistant diseases could have major indirect and long-term consequences.

Page 1058

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

The Viewpoint of Society

The impact of antibiotic resistance on society as a whole is currently poorly understood.[56] According to the

Office of Technology Assessment, antibiotic resistance costs the US $4 billion a year in 1995 currency. However,

as this estimate only took into account patients who were directly affected by the resistance, it would likely be

magnified by a number of times.[57] Further studies on the impact of resistance beyond the patient and hospital

levels are essential to inform decision-makers.[58]

Future Strategies

Researchers are looking into several novel approaches based on a reevaluation of the dynamics of illness,

prevention, and resistance.[59] Whole genome sequencing (WGS), which makes it possible to quickly identify

resistance pathways and manage bacterial resistance, is one method that has proven crucial for drug

discovery.[60] Another intriguing tactic that stops bacterial infections by interacting with microbial cells is the

recently discovered quorum-quenching (QQ) method.[61] Bacteriophages, also known as viral phage therapy,

have gained popularity recently as a means of lowering the risk of opportunistic infections since they are more

effective than antibiotics and do not damage host organisms, including gut flora .[62]In light of the growing

concerns regarding antibiotic resistance, therapeutic therapy techniques that rely solely on one medicine may not

be adequate to solve the problem.[63] There are several methods for addressing resistance in addition to just

filling the pipeline for new medications. Scholarly research, clinically established recommendations, and

treatments have demonstrated that combination approaches are more effective in addressing multidrug resistance.

[64]

Public education and awareness of global antimicrobial resistance The World Health Organization (WHO)

organizes Awareness Week (WAAW), a global campaign to raise awareness of antimicrobial resistance

(AMR).[65] WAAW takes place annually from November 18–24. The campaign's goals are to educate the public

and encourage improved procedures in order to slow the spread of AMR.[66]AMR occurs when bacteria, viruses,

fungi, and parasites change over time and become resistant to drugs. In addition to making infections more

challenging to treat, this increases the risk of disease spread, severe illness, and death. AMR affects countries of

all economic levels and poses a threat to global public health.[67] The following are some tactics to combat

AMR:

When taking antibiotics, do as your doctor directs. Don't stop taking antibiotics too soon or share unnecessary

prescription medications. Prepare food safely.

Challenges In the Assessment of Treatment Strategies

Despite the fact that the basic biological assumptions are (largely) unchanged, we identify and discuss a number

of issues that affect how treatment plans are ranked below. We illustrate the relevance of these parameters for

the ranking with examples based on the model provided in equation (2.1).[68] We now lack the data to determine

how modeling decisions affect the ranking; for example, we are unable to assert that "including factor X into the

model turns cycling into the most promising strategy." It is not evident from the available research that a

particular decision or situation would consistently favor one method over another (table 1).[69]

The Optimality Criterion

Currently, a variety of optimality criteria are used to evaluate treatment plans. Others concentrate on the dynamics

of the resistant strains (number of patients infected with a resistant strain, emergence or spread of double

resistance), while others concentrate on the overall success of treatment (number of uninfecteds/infecteds in

some time interval or at equilibrium, number of patients who are treated inappropriately, i.e., patients who are

treated with a drug to which the infecting strain is resistant, such as patients in the RA compartment by drug

A).[70] The optimality criterion selection can have a significant impact on the results, as shown in figure 2.

Different treatment approaches may optimize different amounts, and a technique may work well for one objective

but badly for another .So, which criterion ought to be applied? Any of the aforementioned criteria could be

instructive and significant if the objective is to improve our comprehension of evolutionary dynamics. It is

Page 1059

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

challenging to respond to this issue if the objective is to support clinical trials or to draw conclusions that directly

influence practical applications. [71]=Clinical benefits (e.g., infection clearance), costs (e.g., side effects), and

economic expenses are essentially the three considerations that must be considered. In any event, only the first

of these aspects is specifically addressed by the modelingapproach.However, even when concentrating just on

the clinical advantages, a number of factors must be considered, as will be covered below. Additionally, one must

select a criterion that can be used as a clinical endpoint if the goal is to support or direct clinical trials. In clinical

studies, time ranges that would enable us to track the future spread of multiple resistance and see its initial genesis

are frequently impractical. We assume that long enough clinical studies can be carried out in the discussion that

follows.[72]

Nevertheless, it should be remembered that this could be problematic in practice, making it impossible to define

a relevant clinical endpoint, at least when several resistant strains have not yetappeared. This highlights once

more how crucial modeling is in situations without such restrictions.

CONCLUSION

Antibiotic resistance poses a severe threat to global health, with rising incidences of resistant infections

undermining decades of medical progress. The review emphasizes the necessity of a comprehensive strategy that

includes increased surveillance, responsible antibiotic use, alternative therapy research, and robust policy

frameworks to prevent antibiotic abuse in agriculture and healthcare. The world runs the risk of returning to a

time when common infections could once again become incurable if prompt and coordinated efforts are not made

to reduce antibiotic resistance. In order to retain the effectiveness of present antibiotics and create new treatments

for future generations, cooperation between the scientific, medical, and policy-making sectors is necessary to

address this challenge.

REFERENCE

1. Fleming A. On the antibacterial action of cultures of Penicillium, with special reference to their use in

the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226–236.

2. Chain E, Florey HW, Gardner AD, Heatley NG, Jennings MA, Orr-Ewing J, et al.

3. Penicillin as a chemotherapeutic agent. Lancet. 1940;236(6104):226–228.

4. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front

Microbiol. 2010;1:134.

5. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev.

2010;74(3):417–433.

6. Ventola CL. The antibiotic resistance crisis. Pharm Ther. 2015;40(4):277–283.

7. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO;

2014.

8. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.

9. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2).

10. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis. Clin Microbiol

Rev. 1997;10(4):781–791.

11. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56(1):20–51.

12. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem. 2009;78:119–146.

13. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs. 2009;69(12):1555–1623.

14. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta.

2009;1794(5):808–816.

15. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents

Chemother. 1989;33(11):1831–1836.

16. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms. Nat Rev Microbiol. 2004;2:95–108.

17. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin

Microbiol Rev. 2002;15(2):167–193.

18. Mah TF, O’Toole GA. Mechanisms of biofilm resistance. Trends Microbiol. 2001;9(1):34–39.

Page 1060

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

19. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135–

138.

20. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med. 2006;119(6):S3–S10.

21. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic

resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.

22. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London:

Review on AMR; 2016.

23. Levin BR, Bonten MJM. Cycling antibiotics may not be good for your health. Proc Natl Acad Sci USA.

2004;101(36):13101–13102.

24. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce

resistance. Proc Natl Acad Sci USA. 2004;101(36):13285–13290.

25. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance.

Proc Natl Acad Sci USA. 1997;94(22):12106–12111.

26. Beardmore RE, Peña-Miller R. Antibiotic cycling versus mixing. PLoS Comput Biol.

2010;6(7):e1000814.

27. Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. Population biological principles of

drug resistance. Lancet Infect Dis. 2011;11(3):236–247.

28. MacLean RC, San Millan A. Microbial evolution and antibiotic resistance. Science.

2019;365(6458):1082–1083.

29. Andersson DI, Hughes D. Antibiotic resistance and its cost. Nat Rev Microbiol. 2010;8:260–271.

30. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic

resistance. Nat Rev Microbiol. 2015;13:42–51.

31. Rice LB. Federal funding for the study of antimicrobial resistance. J Infect Dis. 2008;197(8):1079–1081.

32. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-

resistant infections. Clin Infect Dis. 2008;46(2):155–164.

33. CDC. Antibiotic resistance threats in the United States. Atlanta: CDC; 2019.

34. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe.

Stockholm: ECDC; 2020.

35. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes. Clin Infect Dis.

2006;42(S2):S82–S89.

36. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, et al. Hospital costs of antimicrobial-

resistant infections. Clin Infect Dis. 2009;49(8):1175–1184.

37. Levy SB, Marshall B. Antibacterial resistance worldwide. Nat Med. 2004;10:S122–S129.

38. Davies J. Inactivation of antibiotics and dissemination of resistance genes. Science. 1994;264(5157):375–

382.

39. Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors. Cold Spring Harb Perspect Med.

2016;6(8):a025247.

40. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–

201.

41. Wright GD. Antibiotic resistance in the environment. Nat Rev Microbiol. 2010;8:260–271.

42. Baquero F, Martínez JL, Cantón R. Antibiotics and resistance in water environments. Curr Opin

Biotechnol. 2008;19(3):260–265.

43. Martínez JL. Environmental pollution by antibiotics and resistance determinants. Environ Pollut.

2009;157(11):2893–2902.

44. Marshall BM, Levy SB. Food animals and antimicrobials. Clin Microbiol Rev. 2011;24(4):718–733.

45. Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in

antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112(18):5649–5654.

46. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and

environment. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140083.

47. Otto M. MRSA virulence and spread. Nat Rev Microbiol. 2012;10:233–242.

48. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg

Infect Dis. 2011;17(10):1791–1798.

49. World Health Organization. Global tuberculosis report. Geneva: WHO; 2022.

50. Gillespie SH. Evolution of drug resistance in tuberculosis. Lancet Infect Dis. 2002;2(5):298–306.

Page 1061

www.rsisinternational.org

INTERNATIONAL JOURNAL OF LATEST TECHNOLOGY IN ENGINEERING,

MANAGEMENT & APPLIED SCIENCE (IJLTEMAS)

ISSN 2278-2540 | DOI: 10.51583/IJLTEMAS | Volume XV, Issue II, February 2026

51. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, et al. Whole-genome

sequencing for antimicrobial resistance. N Engl J Med. 2012;366:2267–2275.

52. Didelot X, Bowden R, Wilson DJ, Peto TEA, Crook DW. Transforming clinical microbiology with

genome sequencing. Nat Rev Genet. 2012;13:601–612.

53. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance in biofilms. Int J Antimicrob

Agents. 2010;35(4):322–332.

54. Bjarnsholt T. The role of biofilms in chronic infections. APMIS. 2013;121:1–58.

55. Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev

Biol. 2005;21:319–346.

56. LaSarre B, Federle MJ. Exploiting quorum sensing to combat bacteria. Microbiol Mol Biol Rev.

2013;77(1):73–111.

57. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of infections. Bacteriophage.

2011;1(2):66–85.

58. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and resistance. Future Microbiol. 2013;8(6):769–

783.

59. Bikard D, Barrangou R. Using CRISPR–Cas systems to combat AMR. Nat Rev Microbiol. 2017;15:513–

525.

60. Wright GD. Q&A: Antibiotic resistance. Nat Rev Microbiol. 2007;5:175–186.

61. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al.

62. Understanding drivers of AMR. Lancet. 2016;387(10014):176–187.

63. Prescott JF. Antimicrobial use in food and companion animals. Anim Health Res Rev. 2008;9(2):127–

133.

64. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics. N Engl J Med. 2013;368:299–302.

65. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs. Nat Rev Drug Discov.

2007;6:29–40.

66. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71–109.

67. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs. Clin

Infect Dis. 2009;48(1):1–12.

68. Llor C, Bjerrum L. Antimicrobial resistance: risk of overprescribing. Am J Infect Control.

2014;42(8):S159–S164.

69. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care.

BMJ. 2010;340:c2096.

70. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe. Lancet.

2005;365(9459):579–587.

71. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. IDSA guidelines for

antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.

72. Dyar OJ, Huttner B, Schouten J, Pulcini C. Stewardship strategies. Clin Microbiol Infect.

2017;23(11):793–798.

73. Read AF, Day T, Huijben S. Evolution of drug resistance and treatment strategies. Proc Natl Acad Sci

USA. 2011;108(S2):10871–10878.

74. zur Wiesch PA, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, et al. Classic resistance

mutations with low fitness cost. Mol Biol Evol. 2015;32(2):457–468.